Pharma cos may report subdued performance in Q2 FY17: Report

Domestic pharmaceutical companies are likely to report subdued sales, EBITDA and PAT figures in the second quarter of this fiscal, even as the formulations business may see a strong recovery, Reliance Securities said in its report.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney IThe Winning Leap SME Special
Moneycontrol

Home » News » Earnings » Brokerage Results Estimates

Oct 17, 2016, 10.20 AM | Source: PTI

Pharma cos may report subdued performance in Q2 FY17: Report

Domestic pharmaceutical companies are likely to report subdued sales, EBITDA and PAT figures in the second quarter of this fiscal, even as the formulations business may see a strong recovery, Reliance Securities said in its report.

Like this story, share it with millions of investors on M3

Pharma cos may report subdued performance in Q2 FY17: Report

Domestic pharmaceutical companies are likely to report subdued sales, EBITDA and PAT figures in the second quarter of this fiscal, even as the formulations business may see a strong recovery, Reliance Securities said in its report.

Post Your Comments

Share Cancel

Pharma cos may report subdued performance in Q2 FY17: Report
Domestic pharmaceutical companies are likely to report subdued sales, EBITDA and PAT figures in the second quarter of this fiscal, even as the formulations business may see a strong recovery, a report said.

"We expect the pharmaceutical companies to report subdued performance on sales, EBITDA and PAT front in Q2 FY17 led by the quiet US business on lack of fresh ANDA approvals due to the pending US FDA issues.

"Pharma companies are likely to report sales, EBITDA and PAT growth of 10.2 per cent YoY, 9.4 per cent YoY and 14.3 per cent YoY, respectively in Q2 FY17," Reliance Securities said in its report here.

"However, industry expects strong recovery in domestic formulations business for most companies under our coverage driven by strong monsoon, while favourable y-o-y movement in non-USD currencies and new drugs approvals will drive growth in emerging markets," the report said.

It said EBITDA margins will continue to be under pressure on account of increased R&D spending and adverse product-mix.

"We continue to remain positive on long-term prospects of the pharma sector and recommend being stock-specific," it added.

The US remains mainstay for most companies, contributing 55-60 per cent of total exports.

Measures like aggressive R&D spend and scale-up in complex ANDA filings are considered to be the key re-rating triggers, it said.

However, few operational metrics have exhibited lack of momentum like critical facilities under US FDA lens, channel consolidation and slowdown in approvals.

While Sun Pharma Halol warning letter and Cadila's Moraiya warning letter are awaiting re-inspection from the US FDA, Dr Reddy's pending Form 483 to three plants is still undergoing Corrective and Preventive Action (CAPA) process and it is expected to submit re-inspection request shortly.

Lupin is awaiting the US FDA resolution for its Goa plant.

"The US revenue for the companies under our coverage universe is expected to decline sequentially by 5-6 per cent owing to increased competition leading to price erosion in base product portfolio, Gleevec/Glumetza 180 days exclusivity ends and lack of meaningful launches," it added.

Pharma companies are likely to witness strong recovery in domestic formulations business.

"We expect strong recovery in India formulations business for most companies driven by strong monsoon," it said.

The Indian pharma market has reported strong growth of 15 per cent and 18 per cent in July and Aug, respectively.

It is expected to witness 16-17 per cent CAGR in next few years, led by new product launches.

Buy, Hold, Sell ? Hear it first on M3
Pharma cos may report subdued performance in Q2 FY17: Report

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login